AB Science S.A. (EPA:AB)

France · Delayed Price · Currency is EUR

1.352

-0.008 (-0.59%)

At close: Feb 27, 2026

0.75% (1Y)

Market Cap	98.62M
Revenue (ttm)	1.03M
Net Income (ttm)	-8.54M
Shares Out	72.95M
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	70,099
Average Volume	125,568
Open	1.364
Previous Close	1.360
Day's Range	1.352 - 1.378
52-Week Range	0.970 - 1.730
Beta	1.38
RSI	50.31
Earnings Date	May 7, 2026

About AB Science

AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company’s lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyotrophic lateral sclerosis, progressive forms of multiple sclerosis, Alzheimer’s disease, and indolent systemic mastocytosis, as well as in Phase 2 tria... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2001

Employees 36

Stock Exchange Euronext Paris

Ticker Symbol AB

Full Company Profile

Financial Performance

In 2024, AB Science's revenue was 1.07 million, an increase of 10.52% compared to the previous year's 970,000. Losses were -7.83 million, -34.66% less than in 2023.

Financial Statements

News

Q4 2025 Fingerprint Cards AB Earnings Call Transcript

15 days ago - GuruFocus